Biosergen AS (BIOSGN) - Total Assets
Based on the latest financial reports, Biosergen AS (BIOSGN) holds total assets worth Skr21.16 Million SEK (≈ $2.28 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Biosergen AS service its debt to assess how comfortably operating cash covers total debt obligations.
Biosergen AS - Total Assets Trend (2019–2025)
This chart illustrates how Biosergen AS's total assets have evolved over time, based on quarterly financial data. See Biosergen AS net assets for net asset value and shareholders' equity analysis.
Biosergen AS - Asset Composition Analysis
Current Asset Composition (December 2025)
Biosergen AS's total assets of Skr21.16 Million consist of 102.0% current assets and -2.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 72.6% |
| Accounts Receivable | Skr6.21 Million | 29.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Biosergen AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIOSGN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biosergen AS's current assets represent 102.0% of total assets in 2025, an increase from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 72.6% of total assets in 2025, down from 78.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 29.3% of total assets.
Biosergen AS Competitors by Total Assets
Key competitors of Biosergen AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Biosergen AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 14.25 | 0.04 |
| Quick Ratio | 1.95 | 14.25 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr10.48 Million | Skr49.14 Million | Skr-6.29 Million |
Biosergen AS - Advanced Valuation Insights
This section examines the relationship between Biosergen AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.61 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -60.0% |
| Total Assets | Skr21.16 Million |
| Market Capitalization | $1.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biosergen AS's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biosergen AS's assets decreased by 60.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biosergen AS (2019–2025)
The table below shows the annual total assets of Biosergen AS from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr21.16 Million ≈ $2.28 Million |
-59.97% |
| 2024-12-31 | Skr52.85 Million ≈ $5.69 Million |
+633.93% |
| 2023-12-31 | Skr7.20 Million ≈ $774.94K |
-78.69% |
| 2022-12-31 | Skr33.79 Million ≈ $3.64 Million |
+14.60% |
| 2021-12-31 | Skr29.49 Million ≈ $3.17 Million |
+514.68% |
| 2020-12-31 | Skr4.80 Million ≈ $516.23K |
-28.17% |
| 2019-12-31 | Skr6.68 Million ≈ $718.72K |
-- |
About Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.